| Original language | English |
|---|---|
| Pages (from-to) | 49-52 |
| Number of pages | 4 |
| Journal | Annals of Allergy, Asthma and Immunology |
| Volume | 120 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2018 |
Bibliographical note
Funding Information:Disclosures: The following is a summary of interests disclosed on Work Group members' conflict of interest disclosure statements (not including information concerning family member interests). Completed conflict of interest disclosure statements are available on request and are available at https://www.allergyparameters.org/ . Conflicts of interest disclosure statements for Joint Task Force on Practice Parameters (JTFPP) are also available there. Dr Greenhawt is supported by grant K08HS024599 from the Agency for Healthcare Quality and Research; is an expert panel and coordinating committee member of the National Institute of Allergy and Infectious Diseases–sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for the Canadian Transportation Agency and Aimmune Therapeutics; is a member of physician/medical advisory boards for Aimmune, Nutricia, Kaleo Pharmaceutical, Intrommune, Nestle, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, the Western/Pennsylvania/Aspen/New York/Swineford allergy societies, the ACAAI, and the EAACI; and is a member of the JTFPP. Dr Turner is in receipt of a Clinician Scientist Award funded by the UK Medical Research Council (MR/K010468/1). He has received funding from the UK Departments of Health policy research program (National Vaccine Evaluation Consortium); the European Union's Seventh Framework Program for research, technological development, and demonstration (grant agreement 312147, iFAAM project); End Allergies Together, a 501(c)(3) nonprofit organization; and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare National Health Service (NHS) Trust and Imperial College London. No other disclosures were reported. The JTFPP recognizes that experts in a field are likely to have interests that could come into conflict with development of a completely unbiased and objective practice parameter. To take advantage of that expertise, a process has been developed to prevent potential conflicts from influencing the final document in a negative way. At the workgroup level, members who have a potential conflict of interest either do not participate in discussions concerning topics related to the potential conflict or, if they do write a section on that topic, the workgroup completely rewrites it without their involvement to remove potential bias. In addition, the entire document is reviewed by the JTFPP and any apparent bias is removed at that level. Finally, the practice parameter is sent for review by invited reviewers and anyone with an interest in the topic by posting the document on the websites of the ACAAI and the AAAAI. The JTFPP is a 12-member taskforce consisting of 6 representatives assigned by the AAAAI and 6 by the ACAAI. This taskforce oversees the development of practice parameters, selects the workgroup chair(s), and reviews drafts of the parameters for accuracy, practicality, clarity, and broad utility of the recommendations for clinical practice.
